Get the Stockscreener App
26.80
4.83%
-1.36
After Hours:
26.85
0.05
+0.19%
Viking Therapeutics Inc stock is traded at $26.80, with a volume of 2.84M.
It is down -4.83% in the last 24 hours and down -4.08% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$28.16
Open:
$27.72
24h Volume:
2.84M
Relative Volume:
0.73
Market Cap:
$3.01B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-28.82
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-0.67%
1M Performance:
-4.08%
6M Performance:
-49.38%
1Y Performance:
-56.62%
1-Day Range:
$26.55
$27.73
1-Week Range:
$26.55
$28.33
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
26.80 | 3.03B | 0 | -99.15M | -74.25M | -0.93 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM (NVDA:NASDAQ) - Seeking Alpha
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade) - Seeking Alpha
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus
Viking Therapeutics Lines Up Presentations at Goldman Sachs, William Blair Healthcare Conferences - Stock Titan
Viking Therapeutics Holds Annual Stockholders Meeting - TipRanks
Viking Therapeutics: Buy It For The Future And Ignore The Noise (NASDAQ:VKTX) - Seeking Alpha
(VKTX) On The My Stocks Page - news.stocktradersdaily.com
Better Weight Loss Stock: Amgen or Viking Therapeutics? - MSN
Viking Therapeutics: Weight-Loss Story Remains Intact (NASDAQ:VKTX) - Seeking Alpha
Bank of America Corp DE Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts - Seeking Alpha
BNP Paribas Financial Markets Has $1.88 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Viking Therapeutics (VKTX) Stock Rises Amid Novo Nordisk CEO Cha - GuruFocus
Why Viking Therapeutics Stock Bumped 3% Higher Today - Mitrade
When (VKTX) Moves Investors should Listen - news.stocktradersdaily.com
Viking Therapeutics Stock May Struggle After As-Expected Report - MSN
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - The Motley Fool
Dimensional Fund Advisors LP Has $4.06 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of “Buy” by Analysts - Defense World
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - The Globe and Mail
3 Monster Stocks in the Making - Yahoo Finance
Hsbc Holdings PLC Sells 9,437 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Why Viking Therapeutics (VKTX) Stock is Gaining Today - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - Yahoo
Viking Therapeutics (VKTX) Sees Unusual Options Activity | VKTX Stock News - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher In April - Barchart.com
Why Viking Therapeutics Stock Was Victorious This Week - MSN
(VKTX) Investment Report - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Sees 20% Stock Surge Despite Financial Losses - GuruFocus
Why Viking Therapeutics (VKTX) Stock is Rising Today - GuruFocus
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking Therapeutics (VKTX) Sees Surge in Call Options Trading | VKTX Stock News - GuruFocus
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025 - simplywall.st
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - The Globe and Mail
This Soaring Stock Just Delivered More Good News. Time to Buy? - AOL.com
Where Will Viking Therapeutics Be in 3 Years? - Yahoo Finance
1 Beaten-Down Stock to Buy and Hold for 10 Years - AOL.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):